SCHEMBL14616164

SCHEMBL14616164

CO[C@@H]1C=CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755809 1.00
SCHEMBL17304902 0.91 NPC1 (0.30)
SCHEMBL10912018 0.91 NPC1 (0.30)
SCHEMBL13279596 0.91 NPC1 (0.30)
SCHEMBL13279599 0.91 NPC1 (0.30)
SCHEMBL10912014 0.91 NPC1 (0.30)
SCHEMBL3682828 0.84
SCHEMBL11519767 0.79
SCHEMBL504183 0.79
SCHEMBL2538119 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210206790-A1 ORGANOMETALLIC COMPOUNDS FOR THE MANUFACTURE OF A SEMICONDUCTOR ELEMENT OR ELECTRONIC MEMORY UMICORE AG & CO, KG (DE) 2021-07-08 US disclosed
US-20070032653-A1 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) 2007-02-08 US disclosed